scholarly journals Recent Advances in Migraine Therapy

Migraine ◽  
2020 ◽  
Author(s):  
Balaji Ommurugan ◽  
Vanishree Rao
Keyword(s):  
Clinical Trials ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Acute Treatment ◽  
Migraine Prophylaxis ◽  
Treatment Modalities ◽  
Channel Blockers ◽  
Recurrent Headache ◽  
Inflammatory Drugs ◽  
Β Blockers

Migraine characterized by recurrent headache episodes presents with aura or without. Various treatment modalities ranging from 5-HT1B/1D agonists, nonsteroidal anti-inflammatory drugs (NSAIDs), to steroids are available for acute treatment of migraine. Prophylaxis for chronic cases usually encompasses β blockers, calcium channel blockers, and antiepileptics. Many nutraceutical preparations are helpful in migraine, including riboflavin and vitamin B12. This review focuses on the newer agents available for treatment of migraine with some insights into their clinical trials.

scholarly journals A COMPLETE REVIEW OF MIGRAINE

2017 ◽  
Vol 10 (10) ◽  
pp. 57
Author(s):  
Balaji Ommurugan ◽  
Amita Priya ◽  
Laxminarayana Kurady Bairy
Keyword(s):  
Clinical Trials ◽  
Vitamin B12 ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Acute Treatment ◽  
Migraine Prophylaxis ◽  
Treatment Modalities ◽  
Channel Blockers ◽  
Inflammatory Drugs ◽  
Β Blockers

Migraine characterized by recurrent headaches present with aura or without aura. Various treatment modalities ranging from 5-hydroxytryptamine 1B/1D agonists, non-steroidal anti-inflammatory drugs to steroids are available for acute treatment of migraine. Prophylaxis for chronic cases is usually with β blockers, calcium channel blockers, and antiepileptics. Even many nutraceutical preparations are helpful in migraine including riboflavin, vitamin b12. This review focuses on the newer agents available for treatment of migraine with some sight into their clinical trials.

Cardiotoxicity with antihypertensive drugs (literature review) Part 1. Calcium channel blockers and beta-blockers

2021 ◽  
pp. 12-19
Author(s):  
A. N. Esaulenko ◽  
A. Yu. Moiseeva ◽  
A. A. Ivannikov ◽  
I. V. Bratischev ◽  
Kh. G. Alidzhanova
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Antihypertensive Drugs ◽  
Beta Blockers ◽  
Research Literature ◽  
Channel Blockers ◽  
Distinctive Features ◽  
Experimental Pharmacology ◽  
Myocardial Insufficiency ◽  
Β Blockers

The effect of hypotensive drugs overdose on cardiovascular system is poorly studied; it should undergo clinical, experimental pharmacology and toxicology together with cardiology. There is too little information about cardiotoxicity of beta-blockers (β-blockers) and calcium channel blockers (CCB) in existing research literature. Intoxication from these groups of drugs causes similar severe hemodynamic abnormalities and myocardial insufficiency, however pathophysiological mechanisms of these abnormalities are not thoroughly studied. The review highlights how difficult it is to identify toxic level and distinctive features of clinical evidence of intoxication. Methods of diagnosis as well as β-blockers and CCB overdose treatment are discussed.

Does QTc Interval Predict the Response to β-Blockers and Calcium Channel Blockers in Hypertensives?

Heart Disease ◽  
2003 ◽  
Vol 5 (4) ◽  
pp. 244-252 ◽  
Author(s):  
Maxime Lamarre-Cliche ◽  
Yves Lacourcière ◽  
Jacques de Champlain ◽  
Luc Poirier ◽  
Pierre Larochelle
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers ◽  
Qtc Interval ◽  
Β Blockers

scholarly journals Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials

2005 ◽  
Vol 16 (3 suppl 1) ◽  
pp. S64-S66 ◽  
Author(s):  
Julián Segura ◽  
José A. García-Donaire ◽  
Luis M. Ruilope
Keyword(s):  
Clinical Trials ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers ◽  
Renal Protection

scholarly journals Calcium channel blockers and β-blockers in relation to Parkinson's disease

2007 ◽  
Vol 13 (3) ◽  
pp. 165-169 ◽  
Author(s):  
Thanh G.N. Ton ◽  
Susan R. Heckbert ◽  
W.T. Longstreth ◽  
Mary Anne Rossing ◽  
Walter A. Kukull ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers ◽  
Β Blockers

scholarly journals The safety of antihypertensive drugs. Retrospective analysis of adverse reactions based on a regional database

2021 ◽  
Vol 27 (2) ◽  
pp. 216-228
Author(s):  
A. V. Matveev ◽  
A. E. Krasheninnikov ◽  
A. V. Ushakov ◽  
E. A. Egorova ◽  
A. G. Dormidor
Keyword(s):  
Calcium Channel ◽  
Retrospective Analysis ◽  
Calcium Channel Blockers ◽  
Adverse Reactions ◽  
Antihypertensive Drugs ◽  
Channel Blockers ◽  
Drug Reactions ◽  
Life Threatening ◽  
Β Blockers ◽  
Design And Methods

Objective. To analyze adverse drug reactions (ADR) occuring in patients taking antihypertensive drugs (AHD).Design and methods. We have analyzed 459 cases of ADR caused by AHD and recorded in the regional database (register) called ARCADe (Adverse Reactions in Crimea, Autonomic Database) during 2011–2018 years.Results. Out of all ADR, 304 cases (3,9 4,4 4,9 % of the total number of cases) were associated with AHD affecting renin-angiotensin-aldosterone system,101 (1,2 1,5 1,8 %) — with calcium channel blockers, and 54 cases (0,6 0,8 1,0 %) — with β-blockers. In the majority of cases, the ADRs were attributed to Enalapril (85 cases) and Amlodipine (76 cases). The analysis of the outcomes showed that serious reactions (life-threatening conditions, hospitalization, and disability) occurred in 72 cases. The remaining 387 ADRs were not considered serious. The majority of reported ADRs were unavoidable reactions of mild severity.

scholarly journals A Systematic Review on 1, 4-Dihydropyridines and its Analogues: An Elite Scaffold

2021 ◽  
Vol 12 (3) ◽  
pp. 3117-3134
Keyword(s):  
Myocardial Infarction ◽  
Systematic Review ◽  
Clinical Trials ◽  
Calcium Channels ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Calcium Influx ◽  
Channel Blockers ◽  
Neuroprotective Effects ◽  
Dihydropyridine Derivatives

1,4-Dihydropyridines are a group of pyridine-based molecules possessing a magnificent set of biological and therapeutic potentials. Belonging to the class of calcium channel blockers, they are known to be effective in the conditions, angina, hypertension, myocardial infarction and show vasodilatory and cardiac depressant effects. Hypotensive, antimicrobial, anticancer, anticoagulant, antioxidant, anticonvulsant, antimalarial, antiulcer, and neuroprotective effects have been reported with their rational use. The effects are precipitated in response to inhibition of calcium channels, gradually restricting calcium influx. Drugs like nifedipine, felodipine, and amlodipine are commonly used clinically. Several other drugs belonging to this class have been under clinical trials. The present review focuses on the various 1,4-dihydropyridine derivatives and their pharmacological actions.

scholarly journals Cost effectiveness analysis of anti-hypertensive drugs used for chronic kidney disease patients

2019 ◽  
Vol 10 (4) ◽  
pp. 2820-2825
Author(s):  
Mohamed Saleem TS ◽  
Sreeja N ◽  
Kiran Karthik J ◽  
Bhanu Sree K
Keyword(s):  
Chronic Kidney Disease ◽  
Cost Effectiveness ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Antihypertensive Drugs ◽  
Incremental Cost Effectiveness Ratio ◽  
Channel Blockers ◽  
Cost Effectiveness Ratio ◽  
Effectiveness Analysis ◽  
Β Blockers

Cost effectiveness analysis branch of pharmacoeconomics is a technique used to aid in decision making between alternatives. A prospective observational study would be conducted in the nephrology department at O.P, Patients with CKD with hypertension, with or deprived of diabetes are included in the study. Patients with drug-induced renal disease or unknown cause. Pregnant women with chronic kidney disease are excluded from the study. The research was conducted in150 patients in which common are men. The mean age of the research people was found to be 51.2 ±7. 02. .It was observed that calcium channel blockers 127 (84.6%), diuretics 51 (34%), α agonists 33 (22%), β blockers 21 (14%), α blockers 17 (11.3%), α+β blockers 10 (6.6%), Angiotensin receptor blockers 3 (2%) and angiotensin-converting enzyme inhibitors 1 (0.6%) were the numerous antihypertensive drugs given to the study people. Incremental Cost-Effectiveness Ratio was assessed, and it was observed that Rs.31.80 was extra required while using diuretics than Calcium Channel Blockers for achieving respective maintenance value. The major classes of antihypertensive drugs prescribed in all of them are CCB+α agonist was found most effective CCB+ Diuretics were the second most effective. Incremental Cost-Effectiveness Ratio was calculated, and it was found that  Rs.4.40 was Extra needed to attaining essential upkeep of blood pressure. Pharmacoeconomic study shows that Calcium channel blockers were the utmost cost-effective antihypertensive in CKD patients when linked to other antihypertensive drugs. In two-drug combination therapy, CCB+α agonist was found most effective.

scholarly journals Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension

Hypertension ◽  
2021 ◽  
Author(s):  
Leah B. Rethy ◽  
Matthew J. Feinstein ◽  
Chad J. Achenbach ◽  
Raymond R. Townsend ◽  
Adam P. Bress ◽  
...  
Keyword(s):  
Heart Failure ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Ace Inhibitor ◽  
Hazard Ratio ◽  
Hypertension Management ◽  
Channel Blockers ◽  
Β Blocker ◽  
Incident Heart Failure ◽  
Β Blockers

Given unique pathways contributing to hypertension among people with HIV, we sought to determine whether antihypertensive class was associated with cardiovascular disease (CVD) events among people with HIV. Among veterans with HIV and incident hypertension (2000–2018), we used propensity-score matching to evaluate risk of (1) incident/recurrent CVD or death, (2) incident CVD, and (3) incident heart failure by antihypertensive class. In supplementary analyses, we performed stratified analyses by race and chronic kidney disease status. Among 8041 veterans, 24% were initiated on ACE (angiotensin-converting enzyme) inhibitor/ARB (angiotensin receptor blocker) monotherapy, 23% on thiazide/thiazide-like diuretic monotherapy, 13% on β-blocker monotherapy, and 11% on calcium channel blocker monotherapy. Over a median of 6.5 years, 25% experienced a CVD event. β-blockers, but not calcium channel blockers or diuretics, were associated with an increased risk of incident CVD compared with ACEs/ARBs (hazard ratio [95% CI], β-blockers 1.90 [1.24–2.89]; calcium channel blockers 1.02 [0.77–1.34]; diuretics 1.06 [0.86–1.31]); similar hazard ratio were noted for incident/recurrent CVD or death. In veterans without chronic kidney disease, ACE inhibitor/ARBs were associated with a lower risk of incident heart failure compared with all other classes (hazard ratio [95% CI]: β-blockers, 1.52 [1.11–2.09]; calcium channel blockers 1.48 [1.00–2.19]; diuretics 1.52 [1.07–2.16]). In conclusion, we observed high rates of CVD events in people with HIV with hypertension and a high prevalence of β-blocker use for initial hypertension management, even among those without indications. Our findings highlight the potential harm associated with β-blockers and the possible benefit associated with ACE inhibitor/ARBs for hypertension management in people with HIV. Prospective and randomized trials are needed to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document